Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised …

EEW Cohen, D Soulières, C Le Tourneau, J Dinis… - The Lancet, 2019 - thelancet.com
Background There are few effective treatment options for patients with recurrent or
metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour …

[HTML][HTML] Immune checkpoint inhibitors: therapeutic advances in melanoma

I Marquez-Rodas, P Cerezuela, A Soria… - Annals of …, 2015 - ncbi.nlm.nih.gov
In recent years, new strategies for treating melanoma have been introduced, improving the
outlook for this challenging disease. One of the most important advances has been the …

Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death …

A Arance, L De La Cruz-Merino… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE Effective treatments are needed for melanoma that progresses on inhibitors of
programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II …

[HTML][HTML] Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)

E Espinosa, I Márquez-Rodas, A Soria… - Annals of …, 2017 - ncbi.nlm.nih.gov
Immunotherapy has become a key element in the treatment of several tumors, such as lung
carcinoma and melanoma. Immunotherapy, unlike classical chemotherapy and targeted …

[HTML][HTML] Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

M Gonzalez-Cao, T Puertolas, M Riveiro… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint
inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown …

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR

M Vizoso, HJ Ferreira, P Lopez-Serra, FJ Carmona… - Nature medicine, 2015 - nature.com
Metastasis is responsible for most cancer-related deaths, and, among common tumor types,
melanoma is one with great potential to metastasize. Here we study the contribution of …

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

C Balana, MA Vaz, J Manuel Sepúlveda… - Neuro …, 2020 - academic.oup.com
Background Standard treatment for glioblastoma is radiation with concomitant and adjuvant
temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide …

[HTML][HTML] Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

M Gonzalez-Cao, C Mayo de Las Casas… - Nature …, 2021 - nature.com
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated
survival benefit in patients with advanced melanoma harboring activating BRAF mutations …

Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.

JM Piulats Rodriguez, M Ochoa de Olza, M Codes… - 2014 - ascopubs.org
9033 Background: Uveal melanoma is the most common primary intraocular malignant
tumor in adults. Overall survival (OS) at 5 years is 62% due to high incidence of liver …

[HTML][HTML] Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE …

V Grünwald, D Chirovsky, WY Cheung, F Bertolini… - Oral oncology, 2020 - Elsevier
Objectives Given a lack of universally-accepted standard-of-care treatment for patients with
recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study …